Prospective Clinical Study of the Relationship Between Cancer Driving Mutations Found in Endometriotic Implants and the Development of Progesterone Resistance
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Endometriosis
- Sponsor
- Johns Hopkins University
- Enrollment
- 135
- Locations
- 3
- Primary Endpoint
- Number of somatic cancer driver mutations in progesterone-resistant versus progesterone-sensitive endometriosis lesions.
- Status
- Active, not recruiting
- Last Updated
- 10 months ago
Overview
Brief Summary
This study will test the hypothesis that the molecular changes present in ectopic endometriosis lesions correlate with progesterone-resistant disease (using the criteria defined in this study) and are present in matched eutopic endometrium.
Detailed Description
Tissues from 100 patients with endometriosis will be analyzed with droplet digital PCR (ddPCR) targeted sequencing and responders (n=50) will be compared to non-responders (n=50) after controlling confounding factors. From a subset of the 100 cases, whole exome sequencing (WES) and Methylation-Specific PCR (MSP)-based methylation profiling on microdissected epithelium and stroma will be performed in matched eutopic and ectopic tissues from 20 patients with known cancer-associated mutations or 20 controls.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Signed informed consent.
- •Gender: female.
- •Age: 18-45 years at the time of signing consent.
- •Clinical or surgical diagnosis of endometriosis undergoing laparoscopy.
- •Controls may not have clinical or surgical diagnosis of endometriosis.
- •Regular menstrual cycles.
- •BMI between 18-40 kg/m
- •Sexually active or have had a previous vaginal exam that used a speculum.
- •English speaking
Exclusion Criteria
- •Use of any kind of steroidal therapy including oral contraceptives, Norplant, estrogen replacement/supplemental therapy, androgens (Danazol, Cyclomen, Danocrine, testosterone) or progesterone. She may not be taking or be on Celebrex.
- •Pregnant.
- •Presence of pelvic infection.
- •Mullerian anomalies with absence of a cervix.
- •History of cancer of the reproductive tract.
- •Presence of undiagnosed uterine bleeding.
- •Treatment with intrauterine device (IUD) or progestin-containing intrauterine device.
Outcomes
Primary Outcomes
Number of somatic cancer driver mutations in progesterone-resistant versus progesterone-sensitive endometriosis lesions.
Time Frame: Six month
Digital droplet PCR will be used to identify somatic cancer-driver mutations with the presence of at least one of KRAS or ARID1A or PIK3CA or PPP2R1A cancer-driver mutations to assess any difference between progesterone-resistant endometriosis and progesterone-sensitive endometriosis.
Secondary Outcomes
- Difference in DNA methylation PCR profile of endometriotic lesions in ectopic versus eutopic endometrium in control versus diseased subjects.(One month)
- Number of cancer driver mutations in eutopic versus ectopic endometrial tissue in control versus diseased subjects(Six month)